Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

461. Hypnosis for schizophrenia. (Abstract)

Hypnosis for schizophrenia. Many people with schizophrenia continue to experience symptoms despite the use of conventional treatments. Alternative therapies such as hypnosis, in conjunction with conventional treatments, may prove beneficial to them.To investigate the use of hypnosis for people with schizophrenia or schizophrenia-like illnesses compared to standard care and other interventions.We searched the Cochrane Schizophrenia Group's Register (January 2003), contacted the Cochrane (...) 2.00 CI 0.2 to 2.15) and had no discernable effect on mental state (n=60, 1 RCT, MD BPRS by 1 week -3.4 CI -11.4 to 4.6), movement disorders or neurocognitive function. Hypnosis was as acceptable as music (Sibelius) by 4 weeks (n=36, RR leaving the study early 5.0, CI 0.3 to 97.4).The studies in this field are few, small, poorly reported and outdated. Hypnosis could be helpful for people with schizophrenia but to ascertain this requires better designed, conducted and reported randomised studies.

2004 Cochrane

462. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Full Text available with Trip Pro

Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Medication used for acute aggression in psychiatry must have rapid onset of effect, low frequency of administration and low levels of adverse effects. Zuclopenthixol acetate is said to have these properties.To estimate the clinical effects of zuclopenthixol acetate for the management of acute aggression or violence thought to be due to serious mental illnesses, in comparison to other drugs used to treat similar (...) conditions.We supplemented past searches of Current Controlled Trials (10/2000), the Cochrane Library (1997) and MEDLINE (1966-1997) and appeals for unpublished data with an update search of the Cochrane Schizophrenia Group's Register of trials (September 2003).All randomised clinical trials involving people thought to have serious mental illnesses comparing zuclopenthixol acetate with other drugs.Data were extracted independently by two reviewers and cross-checked. We calculated fixed effects relative

2004 Cochrane

463. Depot bromperidol decanoate for schizophrenia. (Abstract)

Depot bromperidol decanoate for schizophrenia. Antipsychotic drugs are the mainstay treatment for schizophrenia. Long-acting depot injections of drugs such as bromperidol decanoate are extensively used as a means of long-term maintenance treatment.To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes.Relevant trials were identified by searching (...) Biological Abstracts (1982-1999), Cochrane Library (Issue 2, 1999), Cochrane Schizophrenia Group's Register (May 1999), EMBASE (1980-1999), MEDLINE (1966-1999) and PsycLIT (1974-1999). References of all identified trials were inspected and Janssen-Cilag was contacted in order to identify more trials. An update search was undertaken in October 2003. The Schizophrenia Groups trials register is based on regular searches of BIOSIS Inside; CENTRAL; CINAHL; EMBASE; MEDLINE and PsycINFO; the hand searching

2004 Cochrane

464. Aripiprazole for schizophrenia. (Abstract)

Aripiprazole for schizophrenia. Treatment of people with schizophrenia using older typical antipsychotic drugs such as haloperidol can be problematic. Many fail to respond and more experience disabling adverse effects. Aripiprazole is said to be one of a new generation of atypical antipsychotics with good antipsychotic properties and minimal adverse effects.To evaluate the effects of aripiprazole for people with schizophrenia and schizophrenia-like psychoses.The reviewers searched the Cochrane (...) Schizophrenia Group's Register (May 2003) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. References of all identified studies were inspected for further trials. The authors contacted relevant pharmaceutical companies, the FDA and authors of trials for additional information.All clinical randomised trials comparing aripiprazole with placebo, typical or atypical antipsychotic drugs for schizophrenia and schizophrenia-like psychoses.We extracted data independently

2004 Cochrane

465. Cerebral SPECT in the assessment of patients with schizophrenia

Cerebral SPECT in the assessment of patients with schizophrenia Cerebral SPECT in the assessment of patients with schizophrenia Cerebral SPECT in the assessment of patients with schizophrenia Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere (...) A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Cerebral SPECT in the assessment of patients with schizophrenia. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' objectives This study aims to summarise the available evidence on the use of cerebral SPECT in the assessment of patients with schizophrenia. Authors' conclusions To consider the role of SPECT for the assessment of patients with schizophrenia , it would be necessary to have

2004 Health Technology Assessment (HTA) Database.

466. A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications

A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

467. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database

Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database Zhao Z Y, Namjoshi M, Barber B L, Loosbrock (...) D L, Tunis S L, Zhu B J, Breier A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of atypical antipsychotic agents, olanzapine (OLZ) and risperidone (RIS), for the treatment of patients with schizophrenia. Type

2004 NHS Economic Evaluation Database.

468. Should clozapine continue to be restricted to third-line status for schizophrenia: a decision-analytic model

Should clozapine continue to be restricted to third-line status for schizophrenia: a decision-analytic model Should clozapine continue to be restricted to third-line status for schizophrenia: a decision-analytic model Should clozapine continue to be restricted to third-line status for schizophrenia: a decision-analytic model Wang P S, Ganz D A, Benner J S, Glynn R J, Avorn J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of clozapine as a first-line treatment for patients with schizophrenia experiencing an acute psychotic episode. The comparators were clozapine as a third-line treatment after failure of two conventional antipsychotic agents, and conventional antipsychotics alone (i.e. never using clozapine

2004 NHS Economic Evaluation Database.

469. Assessing cost-effectiveness in mental health: family interventions for schizophrenia and related conditions Full Text available with Trip Pro

Assessing cost-effectiveness in mental health: family interventions for schizophrenia and related conditions Assessing cost-effectiveness in mental health: family interventions for schizophrenia and related conditions Assessing cost-effectiveness in mental health: family interventions for schizophrenia and related conditions Mihalopoulos C, Magnus A, Carter R, Vos T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three family interventions for the treatment of patients with schizophrenia and related conditions were examined. The interventions were behavioural family management (BFM), behavioural intervention for families (BIF), and multiple family groups (MFG). BFM comprised the sequential steps of assessment

2004 NHS Economic Evaluation Database.

470. Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. (Abstract)

Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. Unlike almost every other country in the world, the prevalence of both schizophrenia and suicide in China is higher in women than in men. Schizophrenia and suicide are important public-health problems for China that might be related to each other. We present prevalence data for schizophrenia and estimate relative and attributable risk of suicide in people with schizophrenia (...) in mainland China.We used data from the national psychiatric epidemiology study, the Ministry of Health's mortality registry, the census, and the national psychological autopsy study to estimate frequencies and rates of schizophrenia, suicide, and suicide in people with schizophrenia aged 15 years and older in mainland China during 1995-99.We estimated 4.25 million people with schizophrenia in China, and 284614 suicides and 28737 suicides in people with schizophrenia yearly. Prevalence of schizophrenia

2004 Lancet

471. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. (Abstract)

Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Results of array studies have suggested abnormalities in expression of lipid and myelin-related genes in schizophrenia. Here, we investigated oligodendrocyte-specific and myelination-associated gene expression in schizophrenia and bipolar affective disorder.We used samples from the Stanley brain collection, consisting of 15 schizophrenia, 15 bipolar affective disorder, and 15 control brains. Indexing-based differential display (...) PCR was done to screen for differences in gene expression in schizophrenia patients versus controls. Results were cross-validated with quantitative PCR, which was also used to investigate expression profiles of 16 other oligodendrocyte and myelin genes in schizophrenia and bipolar disorder. These genes were further investigated with an ongoing microarray analysis.Results of differential display and quantitative PCR analysis showed a reduction of key oligodendrocyte-related and myelin-related genes

2003 Lancet

472. [Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation]. (Abstract)

[Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation]. 12587355 2003 03 25 2015 11 19 0013-7006 28 Spec No 2 Pt 2 2002 Sep-Oct L'Encephale Encephale [Longitudinal comparative study of risperidone vs classical neuroleptics in the treatment of schizophrenia: 24 months of observation]. S31-2 Bouchard R H RH Polyclinique Sainte-Anne, 65, rue Sainte-Anne, 2e étage, Québec, G1R 3X5. fre Clinical Trial Comparative Study (...) Journal Article Randomized Controlled Trial Etude comparative longitudinale de la rispéridone versus les neuroleptiques classiques dans le traitement de la schizophrénie: 24 mois d'observation. France Encephale 7505643 0013-7006 L6UH7ZF8HC Risperidone U42B7VYA4P Chlorpromazine IM Adult Basal Ganglia Diseases chemically induced diagnosis Chlorpromazine adverse effects therapeutic use Cohort Studies Follow-Up Studies Humans Risperidone adverse effects therapeutic use Schizophrenia diagnosis drug therapy

2003 L'Encephale Controlled trial quality: uncertain

473. Genes for schizophrenia? Recent findings and their pathophysiological implications. (Abstract)

Genes for schizophrenia? Recent findings and their pathophysiological implications. Schizophrenia is highly heritable, but the genes have remained elusive. Identifying the genes is essential if the pathogenesis and pathophysiology of schizophrenia is finally to be understood, and to give the prospect of more effective treatment.H Stefansson and colleagues (Am J Hum Genet 2002; 71: 877-92) showed association of the neuregulin (NRG1) gene with schizophrenia. Other recent papers describe six (...) of each gene, epistatic effects, and functional interactions between the gene products, all need investigation. Confirmation that any of the genes is a true susceptibility gene for schizophrenia could trigger the same rapid therapeutic progress as has occurred recently in Alzheimer's disease.

2003 Lancet

474. Depot risperidone for schizophrenia. (Abstract)

Depot risperidone for schizophrenia. Risperidone is the first new generation antipsychotic drug made available in a long acting injection.To examine the clinical effects of depot risperidone for people with schizophrenia and schizophrenia-like psychoses.We searched the Cochrane Schizophrenia Group's Register (December 2002), references of all included studies, and contacted industry and authors of included studies.Randomised clinical trials comparing depot risperidone with other treatments (...) for people with schizophrenia and/or schizophrenia-like psychoses.Two reviewers independently inspected citations and/or abstracts, ordered papers, re-inspected and quality assessed the results, and extracted data. For dichotomous data, we calculated the relative risk (RR), the 95% confidence interval (CI) and, where appropriate, the number needed to treat (NNT), on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD).One study (n=400) compared depot risperidone

2003 Cochrane

475. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. (Abstract)

Antipsychotic drug treatment for elderly people with late-onset schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of schizophrenia that started late in life and prognosis may be made worse by delay and avoidance of treatment.To assess the effects of antipsychotic drugs for elderly people with late-onset schizophrenia.We searched the Cochrane Schizophrenia Group trials register (September 2002). This register is compiled by methodical searches of BIOSIS, Cochrane (...) (within five years) diagnosis of schizophrenia or schizophrenia like illnesses such as delusional disorder, schizoaffective disorder, schizophreniform psychosis or paraphrenia.All citations were inspected by the principal reviewer (SA) and papers ordered and re-inspected (by IA, NAQ, SP) to ensure reliable selection. Methodological quality of trials would have been assessed using the Cochrane Reviewers' Handbook criteria and data would have been independently extracted. Data were to have been excluded

2003 Cochrane

476. Lithium for schizophrenia. (Abstract)

Lithium for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, among them lithium.To review the effects of lithium for the treatment of schizophrenia and schizophrenia-like psychoses.The reviewers searched the Cochrane Schizophrenia Group's register (March 2002). This register is compiled by methodical searches of BIOSIS, CINAHL, Dissertation abstracts (...) , EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings. We also contacted pharmaceutical companies and authors of relevant studies to identify further trials and to obtain original patient data.All randomised controlled trials comparing lithium to antipsychotics or to placebo (or no intervention), whether as sole treatment or as an adjunct to antipsychotic medication for the treatment of schizophrenia

2003 Cochrane

477. New generation antipsychotics for first episode schizophrenia. (Abstract)

New generation antipsychotics for first episode schizophrenia. The new generation antipsychotics are associated with a lower risk of adverse effects compared with drugs such as haloperidol. Many treatment guidelines recommend the use of new generation ('atypical') antipsychotic drugs for people with a first episode of schizophrenia.To examine the effects of the new generation antipsychotics for people with a first episode of schizophrenia or schizophrenia-like psychoses.The reviewers searched (...) the Cochrane Schizophrenia Group's register (March 2002) and the included and excluded studies tables of relevant Cochrane reviews, references of all relevant studies, contacted industry and authors of relevant studies to identify further trials.Randomised clinical trials comparing new generation antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, sulpiride, ziprasidone, zotepine) with conventional antipsychotics for people with a first episode of schizophrenia or schizophrenia

2003 Cochrane

478. Art therapy for schizophrenia or schizophrenia-like illnesses. Full Text available with Trip Pro

Art therapy for schizophrenia or schizophrenia-like illnesses. Medication is the mainstay of treatment for schizophrenia or schizophrenia-like illnesses. Many people, however, continue to experience symptoms in spite of medication. In addition to medication, creative therapies, such as art therapy may be helpful. Art therapy allows exploration of the patient's inner world in a non-threatening way through a therapeutic relationship and the use of art materials. It was mainly developed in adult (...) psychiatric inpatient units and was designed for use with people in whom verbal psychotherapy would be impossible.To review the effects of art therapy as an adjunctive treatment for schizophrenia compared with standard care and other psychosocial interventions.We searched the Cochrane Schizophrenia Group's Register (May 2002), hand searched reference lists and 'Inscape' (the Journal of the British Association of Art Therapists), and contacted relevant authors.All randomised controlled trials that compared

2003 Cochrane

479. Outcome measures and needs assessment tools for schizophrenia and related disorders. Full Text available with Trip Pro

Outcome measures and needs assessment tools for schizophrenia and related disorders. There has been a recent trend to encourage routine outcome measurement and needs assessment as an aid to decision making in clinical practice and patient care. Standardised instruments have been developed which measure clinical symptoms of disorders such as schizophrenia, wider health related quality of life and patients' needs. Such measures might usefully be applied to aid the recognition of psychosocial (...) problems and to monitor the course of patients' progress over time in terms of disease severity and associated deficits in health related quality of life. They might also be used to help clinicians to make decisions about treatment and to assess subsequent therapeutic impact. Such an approach is not, however, without cost and the actual benefit of the adoption of routine outcome and needs assessment in the day-to-day care of those with schizophrenia remains unclear.To establish the value of the routine

2003 Cochrane

480. Compliance therapy: a randomised controlled trial in schizophrenia. Full Text available with Trip Pro

Compliance therapy: a randomised controlled trial in schizophrenia. To evaluate the efficacy of "compliance therapy" for improving adherence to prescribed drug treatment among patients with schizophrenia.Randomised controlled trial.Urban catchment area psychiatric service.94 consecutive admissions of patients with schizophrenia, 56 agreed to participate.Compliance therapy and non-specific counselling, each consisting of 5 sessions lasting 30-60 minutes.Compliance with drug treatment at one year (...) of life.Compliance therapy may not be of benefit to patients with schizophrenia. Attitudes to treatment at baseline predicted adherence one year later and may be a clinically useful tool.

2003 BMJ Controlled trial quality: predicted high